Sanofi $SNY Holdings Boosted by Managed Asset Portfolios LLC

Managed Asset Portfolios LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 0.9% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 608,999 shares of the company’s stock after purchasing an additional 5,458 shares during the quarter. Sanofi accounts for 3.8% of Managed Asset Portfolios LLC’s investment portfolio, making the stock its 7th largest position. Managed Asset Portfolios LLC’s holdings in Sanofi were worth $29,421,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Ameritas Advisory Services LLC acquired a new position in shares of Sanofi during the 2nd quarter valued at about $28,000. Accent Capital Management LLC acquired a new stake in Sanofi during the first quarter worth about $29,000. Eastern Bank raised its stake in Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares during the period. Banque Transatlantique SA acquired a new position in Sanofi in the 1st quarter valued at about $33,000. Finally, Brentview Investment Management LLC purchased a new stake in shares of Sanofi in the 1st quarter valued at approximately $42,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Trading Down 2.2%

SNY opened at $50.66 on Wednesday. Sanofi has a 52 week low of $44.62 and a 52 week high of $60.12. The company has a quick ratio of 0.94, a current ratio of 1.06 and a debt-to-equity ratio of 0.16. The business has a fifty day simple moving average of $49.16 and a 200-day simple moving average of $49.35. The firm has a market cap of $124.40 billion, a P/E ratio of 11.86, a P/E/G ratio of 1.38 and a beta of 0.49.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 24th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The firm had revenue of $14.53 billion for the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter in the previous year, the business earned $2.25 EPS. The company’s quarterly revenue was down 7.5% compared to the same quarter last year. On average, equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Jefferies Financial Group reissued a “buy” rating on shares of Sanofi in a research note on Monday, October 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Tuesday, November 11th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 2nd. Finally, Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $56.00 to $58.00 in a report on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.